Mettler-Toledo International Inc. · MTD · FY2025 Q4 · Calendar Q1 2026

Mettler-Toledo: Growth Holds, but Tariffs Still Pressure Margins

The latest analysis supports a constructive but qualified view: Mettler-Toledo is showing resilient demand in automation, digitalization, service, and onshoring-related areas, while unchanged guidance and ongoing tariff, foreign-exchange, China, and end-market risks temper the outlook.

Reported After market closeNYSEHealthcare $31.07B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $13.36 Consensus $12.80
EPS surprise +4.4% Reported versus consensus
Reported revenue $1.13B Consensus $1.10B
Revenue surprise +2.3% Reported versus consensus

Market reaction

event-close to next-session close
Stock move -0.7% Event window
SPY move +1.9% Same window
Abnormal move -2.6% Stock minus SPY
Volume 1.7× Versus trailing sessions
Subsequent drift -9.1% Up to 20 sessions
MTDSPY benchmark

Ask FN2 about MTD FY2025 Q4

Transcript, numbers and history already loaded

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

Compared with the prior analysis, Q4 growth was 5% in local currency, the service business reached $1 billion, and management highlighted the Vero pipette and X3 Series X-ray launches. The Swiss tariff rate reduction was identified as a near-1% 2026 EPS benefit, while tariff and FX pressures remained.

Guidance delta

Maintained: full-year 2026 guidance was unchanged, with approximately 4% local-currency sales growth, operating margin up 60–70 basis points, and adjusted EPS of $46.05–$46.70.

Key takeaways

  • Q4 sales increased 5% in local currency, with 99% free-cash-flow conversion.
  • Management linked growth to automation, digitalization, onshoring, and the Spinnaker sales program.
  • The service business reached $1 billion and is expected to grow at a mid- to high-single-digit rate in 2026.
  • Tariff and foreign-exchange effects remained margin headwinds, while the Swiss tariff reduction was described as a near-1% 2026 EPS benefit.
  • Management highlighted the Vero electronic pipette, X3 Series X-ray system, and smart weighing indicators.

Management priorities

  • Expand automation and digitalization across laboratory and industrial customers.
  • Roll out the Vero electronic pipette and X3 Series X-ray solutions.
  • Broaden smart weighing and MES integrations.
  • Increase service coverage across the installed base.
  • Continue Spinnaker initiatives and pursue replacement-cycle, onshoring, and emerging-market opportunities.

Follow MTD with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
MTD EPS earnings history estimate and actual scatter chart 9 reported fiscal quarters and 3 future estimate-only quarters. Q1 '24 estimate $7.64 Q1 '24 actual $8.89, beat Q2 '24 estimate $9.03 Q2 '24 actual $9.65, beat Q3 '24 estimate $10.01 Q3 '24 actual $10.21, beat Q2 '25 estimate $9.60 Q2 '25 actual $10.09, beat Q3 '25 estimate $10.66 Q3 '25 actual $11.15, beat Q4 '25 estimate $12.80 Q4 '25 actual $13.36, beat Q1 '26 estimate $8.71 Q1 '26 actual $8.91, beat Q2 '26 estimate $10.85 Q2 '26 actual $11.46, beat Q3 '26 estimate $12.11 Q4 '26 estimate $14.92 Q1 '27 estimate $10.13
Show 1 more >

Analyst Consensus ?

ConsensusHold18 ratings
Bullish844.4%
Neutral1055.6%
Bearish00.0%

1 unmapped firm rating excluded from the percentages.

Analyst 52W Price Targets

$1,515.89Current
$1,100Low
$1,419.73Average
$1,600High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 30, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Morgan Stanley Equal Weight Equal WeightMaintainAug 4, 2026
Wells Fargo Equal Weight Equal WeightMaintainAug 3, 2026
Stifel Buy BuyMaintainAug 3, 2026
Evercore ISI Group Outperform OutperformMaintainAug 3, 2026
Barclays Overweight OverweightMaintainAug 3, 2026
Show 14 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $1,515.89. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
RBC CapitalDan Leonard$1,515$1,405.14 -0.1%Sep 1, 2026
Morgan StanleyKallum Titchmarsh$1,450$1,433.89 -4.3%Aug 4, 2026
BarclaysAnalyst unavailable$1,575$1,416.3 +3.9%Aug 3, 2026
Stifel NicolausDaniel Arias$1,600$1,416.3 +5.5%Aug 3, 2026
JefferiesAnalyst unavailable$1,580$1,412.91 +4.2%Jul 31, 2026
See 26 more

Track every rating change on MTD the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Mettler-Toledo International Inc. (MTD) is a global enterprise dedicated to the production and provision of precision instruments and related services. The company's operations are strategically organized across five geographical divisions: its domestic U.S. market, Swiss operations, Western European activities, Chinese operations, and an 'Other' segment covering remaining territories. Their extensive product portfolio serves diverse scientific and industrial needs. Within the laboratory sphere, Mettler-Toledo supplies a comprehensive array of equipment, including high-precision balances, advanced liquid handling systems (such as pipetting solutions), automated laboratory reactors, titrators, pH meters, sensors and analyzers for process analytics, instruments for evaluating physical properties, thermal analysis systems, and various other analytical tools. These hardware offerings are complemented by LabX, their proprietary software platform designed for managing and analyzing instrument-generated data.…

Historical context

All MTD earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
COO The Cooper Companies, Inc. FY2026 Q3 · Calendar Q3 2026 +2.7% -14.7% CooperCompanies beats expectations as inventory reduction weighs on vision revenue
MDT Medtronic plc FY2027 Q1 · Calendar Q3 2026 +4.3% +1.5% Medtronic raises FY27 outlook as growth broadens across platforms

Latest beats and misses

Who reports next

Get the MTD recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:36:15.940040+00:00
  3. Polygon adjusted daily market bars · 2026-09-30T18:06:11.268519+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-30T18:06:11.265314+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-09-30. For educational purposes only; not investment advice.